Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

* A diagnosis of complicated bacteremia or infective endocarditis * Gram-positive bacteremia at screening with methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) or Streptococci * Treatment with standard of care antibiotics for 72 hours (h) - 10 days * Defervescence for at least 24h and clearance of bacteremia from screening pathogen.

* Embolic events * History of prosthetic valve surgery, cardiac device or prosthetic joint * Left-sided endocarditis due to Staphylococcus aureus (S. aureus) * Large mobile vegetations (\>10 mm) on mitral valves * Perivalvular abscess * Uncomplicated bacteremia due to S. aureus * Gram-negative bacteria or fungi in blood cultures * Heart failure associated with infective endocarditis \[Left Ventricular Ejection Fraction (LVEF) \<40%\] * Intravascular material or removable infection source not intended to be removed within 4 days postrandomization * Planned valve replacement surgery within 3 days of randomization * Refractory shock, significant hepatic insufficiency or severe leukopenia \[Absolute Neutrophil Count (ANC) \< 500 cells/mm\^3\] * Known osteomyelitis * Hypersensitivity to dalbavancin or other drugs in glycopeptide class * Infection with enterococci, coagulase-negative staphylococci, or with organism not susceptible to dalbavancin or vancomycin * Immunosuppression/immune deficiency * Concomitant systemic antibacterial therapy for gram-positive infection other than that allowed in protocol * Pregnant or nursing females.